PSNL
Personalis, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$15.88
+1.47%Year over year
Reported trailing growth
- Revenue
- -13.3%
- EBITDA
- -20.3%
- EBIT
- -58.8%
- EPS
- +14.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +42.8%
- EBITDA
- +11.5%
- EPS
- +14.9%
Three-year CAGR
- Revenue
- +2.3%
- EBITDA
- -1.0%
- EBIT
- -29.0%
- Net income
- +0.0%
- EPS
- +33.6%
- Free cash flow
- -69.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026